rs121913377, BRAF

N. diseases: 480
Disease: Stage III Cutaneous Melanoma AJCC v6 ×
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Stage III Cutaneous Melanoma AJCC v6
CUI: C0278882
Disease: Stage III Cutaneous Melanoma AJCC v6
0.020 GeneticVariation BEFREE In conclusion, there is no prognostic value of BRAF V600E mutation on overall survival in stage I-III melanoma patients, yet its presence might indicate a decreased risk for development of relapse and/or metastasis in stage III melanoma patients. 31058533 2019
Stage III Cutaneous Melanoma AJCC v6
CUI: C0278882
Disease: Stage III Cutaneous Melanoma AJCC v6
0.020 GeneticVariation BEFREE Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvant use of placebo and was not associated with new toxic effects. 28891408 2017